CRXX--This is from May 3, but I'd missed and don't know if it was posted here.
CombinatoRx Inc. /quotes/comstock/15*!crxx/quotes/nls/crxx (CRXX 1.50, +0.06, +4.17%) received FDA approval for Exalgo, a powerful once-a-day painkiller, on March 2. They have already partnered with Mallinckrodt, a subsidiary of Covidien PLC /quotes/comstock/13*!cov/quotes/nls/cov (COV 42.41, +0.66, +1.58%) , to distribute the drug in North America. Mallinckrodt will start shipping any day. CombinatoRx will be collecting substantial royalties, on top of the $40 million milestone payment they already received from Covidien. The royalty flow will move the stock up. Moreover, I think it is highly likely that Covidien will acquire CombinatoRx by the end of 2011, at a substantial multiple of the current price.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.